Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.

Abstract

OBJECTIVE:

The objective of this double-blind, placebo-controlled urodynamic pressure/flow study was to assess the efficacy of short-term treatment with the alpha 1-blocker alfuzosin in outflow obstruction of patients with symptomatic benign prostatic hyperplasia (BPH).

MATERIAL AND METHODS:

Urodynamic pressure/flow parameters were assessed after 2 weeks of placebo run-in, 4 weeks of placebo (47 patients) or 2.5 mg t.i.d. alfuzosin treatment (47 patients), followed by an 8-week extension period with alfuzosin (single-blind).

RESULTS AND CONCLUSION:

Four weeks of alfuzosin treatment significantly increased maximum flow (+29.0%) and decreased detrusor pressure at maximum flow (-30.2%), detrusor opening pressure (-39.4%) and maximum detrusor pressure (-28.7%). Short-term alfuzosin treatment improved outflow conditions in BPH by reducing prostatic urethral obstruction.

• Authors: G Martorana, C Giberti, F Di Silverio, M von Heland, P Rigatti, R Colombo, G Casadei, P Pacifico
• Journal: European urology (Eur Urol) Vol. 32 Issue 1 Pg. 47-53 ( 1997) ISSN: 0302-2838 [Print] Switzerland
• PMID: 9266231 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Adrenergic alpha-Antagonists
• Quinazolines
• alfuzosin

Topics

• Adrenergic alpha-Antagonists (administration & dosage, adverse effects, therapeutic use)
• Aged
• Aged, 80 and over
• Double-Blind Method
• Follow-Up Studies
• Humans
• Male
• Middle Aged
• Prostatic Hyperplasia (drug therapy)
• Quinazolines (administration & dosage, adverse effects, therapeutic use)
• Rheology
• Single-Blind Method
• Urinary Bladder Neck Obstruction (drug therapy)
• Urination (drug effects)
• Urodynamics (drug effects)